Physician profile
Mark C Takata
NPI 1346207289
$38,546.22
in general payments reported to CMS, 2019-2025
43 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what 77% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,941 · 2020: $822 · 2021: $5,351 · 2022: $17K · 2023: $2,149 · 2024: $7,725 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,215 · Food and Beverage: $2,002 · Education: $77.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,215.00 |
| Food and Beverage | $2,002.44 |
| Education | $77.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $17,810.97 | 2019-2025 | Da Vinci Surgical System |
| Medtronic, INC. | $13,061.64 | 2021-2025 | Signia, Maxtack, Absorbatack |
| Ethicon INC. | $2,850.50 | 2019-2021 | |
| Covidien LP | $2,550.21 | 2019-2020 | |
| Applied Medical Resources Corporation | $370.00 | 2022 | |
| Novo Nordisk INC | $214.32 | 2019-2021 | |
| Lilly USA, LLC | $213.80 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Ethicon US, LLC | $126.72 | 2019-2024 | Linx Reflux Management System |
| Davol INC. | $119.98 | 2019-2025 | Phasix Mesh, Arista |
| Vivus LLC | $103.12 | 2019-2023 | Qsymia |
| Nalpropion Pharmaceuticals LLC | $94.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.35 | 2022-2023 | Gattex |
| Abbott Laboratories | $85.33 | 2022-2023 | Freestyle Libre 3 |
| Currax Pharmaceuticals LLC | $69.22 | 2021-2022 | |
| Rhythm Pharmaceuticals, INC. | $62.42 | 2021-2023 | Imcivree |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Takata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.